kabutan

SymBio Pharmaceuticals Limited, January-September (Third Quarter Cumulative) Net Income Loss Widens, July-September Net Income Loss Widens

Thu Oct 31, 2024 3:30 pm JST Earnings

4582 SymBio Pharmaceuticals Limited 【J-GAAP】

Earnings Report

SymBio Pharmaceuticals Limited <4582> [TSE-G] announced its financial results after the market closed on October 31st (15:30). The consolidated net loss for the cumulative third quarter of the fiscal year ending December 2024 (January to September) expanded to a loss of 2.84 billion yen (compared to a loss of 788 million yen in the same period last year).

Based on the third-quarter cumulative performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net loss for the October to December period (4Q) is expected to further decrease to loss of 783 million yen (compared to a loss of 1.17 billion yen in the same period last year).

In the most recent three-month period, from July to September (3Q), the consolidated net loss expanded to a loss of 1.3 billion yen (compared to a loss of 709 million yen in the same period last year). The operating profit/loss margin drastically worsened from -18.8% in the same period last year to -174.6%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2022 7,355 1,588 1,843 1,555 40.0 92.2 Nov 8, 2022 J-GAAP
Jan - Sep, 2023 4,421 -283 -156 -788 -19.9 ー Nov 14, 2023 J-GAAP
Jan - Sep, 2024 1,898 -2,791 -2,759 -2,845 -63.4 ー Oct 31, 2024 J-GAAP
YoY -57.1% -886.2% -1,668.6% -261.0% -218.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2023 2,411 -762 -802 -1,883 -47.2 0 Feb 8, 2024 J-GAAP
Jul - Dec, 2024 Guidance 1,339 -1,983 -2,043 -2,087 -45.5 0 Aug 1, 2024 J-GAAP
YoY -44.5% -160.2% -154.7% -10.8% +3.6%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2022 10,008 1,963 1,999 1,179 30.2 0 Feb 9, 2023 J-GAAP
Dec, 2023 5,589 -811 -736 -1,962 -49.2 0 Feb 8, 2024 J-GAAP
Dec, 2024 Guidance 2,623 -3,702 -3,524 -3,628 -79.2 0 May 7, 2024 J-GAAP
YoY -53.1% -356.5% -378.8% -84.9% -60.9%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 1,243 -234 -222 -709 -17.9 -18.8 Nov 14, 2023 J-GAAP
Oct - Dec, 2023 1,168 -528 -580 -1,174 -29.4 -45.2 Feb 8, 2024 J-GAAP
Jan - Mar, 2024 597 -806 -727 -777 -18.0 -135.0 May 7, 2024 J-GAAP
Apr - Jun, 2024 687 -913 -754 -764 -17.2 -132.9 Aug 1, 2024 J-GAAP
Jul - Sep, 2024 614 -1,072 -1,278 -1,304 -29.1 -174.6 Oct 31, 2024 J-GAAP
YoY -50.6% -358.1% -475.7% -83.9% -62.4%

Related Articles